My watch list
my.chemeurope.com  
Login  

Ryoji Noyori



Ryoji Noyori (野依良治 Noyori Ryōji?) (born September 3, 1938) is a Japanese chemist. He won the Nobel Prize in Chemistry in 2001. Noyori shared half of the prize with William S. Knowles for the study of chirally catalyzed hydrogenations; the second half of the Prize went to K. Barry Sharpless for his study in chirally catalyzed oxidation reactions (Sharpless epoxidation).

Ryoji Noyori was born in Kobe, Japan. He became fascinated with chemistry at the age of 12, after hearing a presentation on nylon. He saw the power of chemistry as being the ability to "make high values from almost nothing". He became a student at Kyoto University, working as an instructor in the research group of Hotosi Nozaki before being appointed associate professor at Nagoya University. After postdoctoral work with Elias J. Corey at Harvard he returned to Nagoya, becoming a full professor in 1972. He is still based at Nagoya, though he is also now president of RIKEN, a multi-site national research initiative with an annual budget of $800 million. In 2005, Noyori became Honorary Doctor at Technical University of Munich and RWTH Aachen University, Germany.

Noyori believes strongly in the power of catalysis and of green chemistry; in a recent article he argues for the pursuit of "practical elegance in synthesis".[1] In this article he states that "our ability to devise straightforward and practical chemical syntheses is indispensable to the survival of our species." Elsewhere he has said that "Research is for nations and mankind, not for researchers themselves." He encourages scientists to be politically active- "Researchers must spur public opinions and government policies toward constructing the sustainable society in the 21st century."[2]

Noyori is currently a chairman of the Education Rebuilding Council, which was set up by Japan's PM Shinzo Abe after he came to power in 2006 [1].

Additional recommended knowledge

Contents

Chemistry

Noyori is most famous for asymmetric hydrogenation using as catalysts complexes of rhodium and ruthenium, particularly those based on the BINAP ligand. (See Noyori asymmetric hydrogenation) Asymmetric hydrogenation of an alkene in the presence of ((S)-BINAP)Ru(OAc)2 is used for the commercial production of enantiomerically pure (97% ee) naproxen, used as an anti-inflammatory drug. The anti-bacterial agent levofloxacin is manufactured by asymmetric hydrogenation of ketones in the presence of a Ru(II) BINAP halide complex.

He has also worked on other asymmetric processes. Each year 400 000 tonnes of menthol are produced (in 94% ee) by Takasago International Co., using Noyori's method for isomerisation of allylic amines.


More recently he and Jessop have developed an industrial process for the manufacture of N,N-dimethylformamide from hydrogen, dimethylamine and supercritical carbon dioxide in the presence of RuCl2(PMe3)4 as catalyst.[3]

See also

  • The Ryoji Noyori Prize

References

  1. ^ R. Noyori, Pursuing practical elegance in chemical synthesis, Chemical Communications, 2005 (14), 1807 - 1811. Abstract
  2. ^ Keynote address, June 23 2005, at the Second International Conference on Green and Sustainable Chemistry, Washington DC.
  3. ^ P. G. Jessop; W. Leitner (Eds.), Chemical Synthesis using Supercritical Fluids, VCH/Wiley, Weinheim, 1999.

List of books available in English

  • Organic synthesis in Japan : past, present, and future : in commemoration of the 50th anniversary of the Society of Synthetic Organic Chemistry, Japan / editor in chief, Ryoji Noyori (1992)
  • Asymmetric catalysis in organic synthesis(1994)


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ryoji_Noyori". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE